AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34000245
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with concurrent temozolomide (75 mg/m2 per day)
Trial: 34000245
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with adjuvant temozolomide (12 4-week cycles of 150-200 mg/m2 on days 1-5)
Trial: 35584872
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide for 24 weeks
Trial: 33060078
Drug: Stand-alone VR
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stand-alone VR (6-week internet-based intervention with weekly online sessions and daily exercises)
Trial: 35383253
Drug: Solacea 19H
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solacea 19H dialyzer with 1/4th of the regular anticoagulation dose
Trial: 34058910
Drug: Laryngoplasty or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laryngoplasty or voice therapy
Trial: 34058910
Drug: Voice therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice therapy alone
Trial: 34010180
Drug: Increasing WBCc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing WBCc tertiles (mean 5.6, 7.5, and 10.1 × 10^9/L)
Trial: 32526017
Drug: tDCS +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tDCS + exercise therapies
Trial: 32526017
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS + exercise therapies
Trial: 36457045
Drug: digital cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: digital cognitive-behavioral therapy for insomnia (dCBT-I)
Trial: 36457045
Drug: clinician-led cognitive-behavioral
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clinician-led cognitive-behavioral therapy for insomnia (CBT-I)
Trial: 36261277
Drug: 2-week interruption
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week interruption in methotrexate treatment
Trial: 36261277
Drug: Continued methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continued methotrexate treatment
Trial: 34554692
Drug: Selenium 200
RxNorm normalized name: SELENIUM 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium 200 µg
Trial: 35452086
Drug: Capecitabine maintenance
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine maintenance therapy using lower dosage and higher frequency
Trial: 33303575
Drug: Anti-PD1 immunotherapy
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anti-PD1 immunotherapy
Trial: 33303575
Drug: Small-molecule inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-molecule inhibitor targeting HO-1
Trial: 33009852
Drug: Take 5
RxNorm normalized name: Chaga Mushroom Mycelium/Cholecalciferol/Cordyceps/Maitake/Reishi/Shiitake 50 MG-3.75 MCG-50 MG-50 MG-50 MG-50 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 5 Minutes treatment (5 to 10 minutes of dedicated communication with parents)
Trial: 33009852
Drug: Take 5
RxNorm normalized name: Chaga Mushroom Mycelium/Cholecalciferol/Cordyceps/Maitake/Reishi/Shiitake 50 MG-3.75 MCG-50 MG-50 MG-50 MG-50 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 5 Minutes treatment
Trial: 34819017
Drug: Monthly fremanezumab
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly fremanezumab (225 mg)
Trial: 34246226
Drug: Quarterly fremanezumab
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Quarterly fremanezumab (225 mg)
Trial: 32880602
Drug: Eribulin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin plus Pembrolizumab (Eribulin 1.4 mg/m2 IV on days 1 and 8 plus Pembrolizumab 200 mg/m2 IV on day 1 of a 21-day cycle)
Trial: 32880602
Drug: Crossover treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover treatment with Pembrolizumab after progression on Eribulin monotherapy
Trial: 32783267
Drug: 0.7% fumaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7% fumaric acid treatment on fiber post surface and 0.7% fumaric acid treatment on dentin surface
Trial: 32783267
Drug: 9% hydrofluoric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9% hydrofluoric acid treatment on fiber post surface and 0.7% fumaric acid treatment on dentin surface
Trial: 32783267
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no conditioning) on dentin surface and 9% hydrofluoric acid treatment on fiber post surface
Trial: 32783267
Drug: 17% EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17% EDTA treatment on dentin surface and 9% hydrofluoric acid treatment on fiber post surface
Trial: 32783267
Drug: 0.7% fumaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7% fumaric acid treatment on dentin surface and 9% hydrofluoric acid treatment on fiber post surface
Trial: 34182194
Drug: OT+XNJ (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OT+XNJ (i.v. 20 ml/daily)
Trial: 34182194
Drug: OT+low dose-YB
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: OT+low dose-YB (oral, 1,000 mg/day)
Trial: 34182194
Drug: OT+high dose-YB
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OT+high dose-YB (oral, 2,000 mg/day)
Trial: 34182194
Drug: XNJ, l-YB,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XNJ, l-YB, h-YB
Trial: 33972573
Drug: PT150 (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT150 (900 mg/day) administered orally for five days
Trial: 32156255
Drug: Personalized dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized dosage of MPH
Trial: 32156255
Drug: MPH over
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MPH over treatment period
Trial: 33305631
Drug: OLNP-06, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLNP-06, 200 mg twice daily
Trial: 33305631
Drug: Placebo, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 200 mg twice daily
Trial: 32701529
Drug: Intraderma injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraderma injection of TXA
Trial: 33260939
Drug: Recommended behavior
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended behavior group (RB group) - drank 200 mL of water every 2 h
Trial: 33260939
Drug: Half amount
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half amount group (HA group) - drank 100 mL of water every 2 h
Trial: 33260939
Drug: High frequency
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High frequency group (HF group) - drank 110 mL of water every 1 h
Trial: 36268614
Drug: Home-based Intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based Intensive Nutrition Therapy (HINT)
Trial: 36268614
Drug: Standard Medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Medical Therapy (SMT)
Trial: 32856209
Drug: Methylprednisolone 16
RxNorm normalized name: methylprednisolone 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 16 mg twice daily for 7 days
Trial: 33980184
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 0.08 mg/kg oxycodone immediately after completion of the surgical procedure
Trial: 33980184
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection (Control group)
Trial: 35184297
Drug: CDX-0159 (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDX-0159 (0.3, 1, 3, and 9 mg/kg)
Trial: 36302893
Drug: HTI vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTI vaccines (DNA.HTI, MVA.HTI, ChAdOx1.HTI)
Trial: 36302893
Drug: HTI vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTI vaccines
Trial: 34336620
Drug: Extracorporeal Shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal Shock Wave Therapy (ECSWT) - three sessions, once a week for three weeks
Trial: 34336620
Drug: Phonophoresis therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonophoresis therapy - ultrasound using hydrocortisone gel 1% over the trigger point, three times a week for three weeks
Trial: 33909860
Drug: Non-fluoridated gel
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fluoridated gel (control)
Trial: 32483058
Drug: Hypnotic cognitive
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic cognitive therapy
Trial: 32483058
Drug: Standard cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cognitive therapy
Trial: 36129032
Drug: Alteplase at
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase at 0.6 mg/kg
Trial: 34969619
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (nonverbal and instrumental music in the forms of taqsim, saz semai, and peshrev at speeds of 60 and 100)
Trial: 32316938
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate 300 mg
Trial: 35141971
Drug: Voice treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice treatment (n = 6)
Trial: 35141971
Drug: Articulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articulation treatment (n = 7)
Trial: 35141971
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n = 6)
Trial: 33197668
Drug: Six weeks
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six weeks of twice‐weekly Swedish Massage Therapy (SMT)
Trial: 33197668
Drug: Additional six
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional six weeks of twice‐weekly Swedish Massage Therapy (SMT)
Trial: 35813441
Drug: Comprehensive care
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive care based on appropriate Chinese medicine techniques
Trial: 34077684
Drug: Ca‐D‐fortified yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca‐D‐fortified yogurt drink (CDY; 1000 IU vitamin D plus 500 mg calcium)
Trial: 34389250
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose of ethambutol (12.5 mg/kg/d)
Trial: 34389250
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of ethambutol (15.4 mg/kg/d)
Trial: 34389250
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of ethambutol
Trial: 34389250
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose of ethambutol
Trial: 34389250
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of ethambutol
Trial: 34423904
Drug: Rapastinel 900
RxNorm normalized name: Rapastinel
DrugBank: Rapastinel (DB11801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapastinel 900 mg
Trial: 34423904
Drug: Rapastinel 1800
RxNorm normalized name: Rapastinel
DrugBank: Rapastinel (DB11801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapastinel 1800 mg
Trial: 34423904
Drug: Alprazolam 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.75 mg (positive control)
Trial: 34423904
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg/kg (clinical comparator)
Trial: 32664290
Drug: Rice and
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice and pea combination (RP, n = 6)
Trial: 36040184
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral electrolyte-carbohydrate nutrition supplement (OECNS)
Trial: 36040184
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (meal nutrition supplements and water)
Trial: 33885704
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) starting dose of 50 Gy in 5 fractions (central lung, mediastinal/cervical lymph node), 45 Gy in 3 fractions (peripheral lung, abdominal-pelvic, liver), and 30 Gy in 3 fractions (bone/osseous, spinal/paraspinal)
Trial: 32072763
Drug: LIK066 (licogliflozin)
RxNorm normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIK066 (licogliflozin) 2.5 mg once daily
Trial: 32072763
Drug: LIK066 (licogliflozin)
RxNorm normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIK066 (licogliflozin) 10 mg once daily
Trial: 32072763
Drug: LIK066 (licogliflozin)
RxNorm normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIK066 (licogliflozin) 25 mg once daily
Trial: 32072763
Drug: LIK066 (licogliflozin)
RxNorm normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIK066 (licogliflozin) 50 mg once daily
Trial: 33237242
Drug: Multilink Speed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multilink Speed (ML)
Trial: 35695053
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous immunoglobulin (IVIG) at a dose of 5 g/day for 3 days (total 15 g or 0.3 g/kg)
Trial: 35695053
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous immunoglobulin (IVIG)
Trial: 34474583
Drug: Rivaroxaban or
RxNorm normalized name: rivaroxaban Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban or rivaroxaban plus an antiplatelet agent
Trial: 34961782
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) 8 mg
Trial: 34961782
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) 8 mg + Etodolac (ETO)
Trial: 34961782
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) 8 mg + Ketorolac (KET)
Trial: 34961782
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) 8 mg + Ibuprofen (IBU)
Trial: 34961782
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) 8 mg + Loxoprofen (LOX)
Trial: 34961782
Drug: Paracetamol 750
RxNorm normalized name: Hydrocodone bitartrate 7.5 mg and paracetamol 750 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 750 mg (rescue analgesics)
Trial: 34287970
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg apraglutide
Trial: 34287970
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg apraglutide
Trial: 34414672
Drug: Enpatoran 1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enpatoran 1, 3, 9, 25, 50, 100, or 200 mg single dose
Trial: 34414672
Drug: Enpatoran 9,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enpatoran 9, 25, or 200 mg once daily for 14 days
Trial: 34414672
Drug: Enpatoran 25
RxNorm normalized name: Enpatoran
DrugBank: Enpatoran (DB16501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enpatoran 25 or 50 mg twice daily for 14 days
Trial: 34414672
Drug: Enpatoran 25
RxNorm normalized name: Enpatoran
DrugBank: Enpatoran (DB16501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enpatoran 25 mg single dose with food
Trial: 34414672
Drug: Enpatoran 200
RxNorm normalized name: Enpatoran
DrugBank: Enpatoran (DB16501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enpatoran 200 mg single dose
Trial: 32942788
Drug: Triamcinolone acetate
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetate (TA) 40 mg
Trial: 32942788
Drug: Triamcinolone acetate
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetate (TA) 20 mg
Trial: 34321056
Drug: Tuina with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuina with herbal ointment
Trial: 34321056
Drug: Herbal ointment
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal ointment (control group)
Trial: 33730928
Drug: 0.1 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 μg/kg
Trial: 33730928
Drug: 0.3 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 μg/kg
Trial: 33730928
Drug: 0.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 μg/kg
Trial: 33730928
Drug: 1.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 μg/kg
Trial: 35380356
Drug: 18 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 g/day of MCT oil
Trial: 34445834
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (400 mg/d)
Trial: 34445834
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group, average calcium intake 400 mg/d)
Trial: 35460145
Drug: Jujube syrup,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jujube syrup, consumed twice a day for 8 weeks
Trial: 35460145
Drug: Placebo, consumed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, consumed twice a day for 8 weeks
Trial: 33183463
Drug: Nanoparticle-loaded edaravone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanoparticle-loaded edaravone treatment (NET)
Trial: 33183463
Drug: Edaravone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone treatment (ET)
Trial: 33094682
Drug: meloxicam IV
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: meloxicam IV 30 mg
Trial: 32726514
Drug: Subcutaneous sarilumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous sarilumab (150 or 200 mg)
Trial: 32726514
Drug: Intravenous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous tocilizumab (4 or 8 mg/kg)
Trial: 32726514
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (sarilumab and tocilizumab)
Trial: 34158245
Drug: Sunitinib 25
RxNorm normalized name: sunitinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 25 mg PO daily with paclitaxel 80 mg/m2 IV weekly ×12 followed by doxorubicin 24 mg/m2 IV weekly + cyclophosphamide 60 mg/m2 PO daily with G-CSF support
Trial: 34452959
Drug: High fibre
RxNorm normalized name: Adult high protein high fibre formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fibre supplement (resistant starch)
Trial: 32796391
Drug: Anti-inflammatory combination
RxNorm normalized name: ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory combination therapy
Trial: 32216832
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) combined with bright light therapy (BLT) - one face-to-face session on sleep strategies, one telephone call, seven email packages, and wearing Luminette® light glasses for 20 minutes each morning for 6 weeks.
Trial: 32216832
Drug: Relaxation audio-enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation audio-enhanced treatment as usual (TAU+) - two relaxation audio tracks via email.
Trial: 36060925
Drug: Crocin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocin (30 mg tablets, three consecutive doses, 1 day before to 1 day after CM exposure)